About us
Services & Solutions
Chemistry Drug Metabolism and Pharmacokinetics (DMPK) Discovery Biology Oncology Pharmacology Biologics
Medicinal Chemistry Parallel Synthesis Peptide Chemistry Computational Chemistry Synthetic Chemistry Analytical Chemistry Scale Up Chemistry
In Vivo PK and TK In Vitro ADME Bioanalytical Service Exploratory Toxicity In Rodents, Dogs and Monkeys Large Molecules Capabilities Bioanalytical Instruments
Fragment Based Drug Discovery (FBDD) Biochemical Assays Cellular Assays Protein Science Assay Technologies Biophysics SPR Safety Pharmacology Screening Services Key Instruments
PDX CDX Orthotopic Models Syngeneic Models Humanized Mouse Models CAR-T and CAR-NK Mouse Models In Vitro Assays
Immunology Inflammation Metabolic NASH/MASH Respiratory Neuroscience
Systematic Antibody Discovery Service
Process R&D Scale Up Synthesis DS Manufacturing
Flow Chemistry Sugar Chemistry Peptide Chemistry Preparative Purification Capacity Process Safety Assessment
Synthetic and Scale Up Chemistry
Kilo and Pilot Scale Production RSM and Intermediates Manufacturing QA EHS
Preformulation Formulation, Analytical, and Process Development Drug Product Manufacturing
Bioavailability Enhancement Modified Release
Commercial Manufacturing
Platforms
News & Resources
Careers
Contact us
×

news

Company News Events Insights Webinars Virtual Tours

Congratulations to Fosun Pharma for Selective BCL-2 Inhibitor FCN-338 Accepted for Clinical Trial

Congratulations to Fochon Pharmaceuticals (Fosun Pharma subsidiary) for their selective BCL-2 inhibitor FCN-338 and tablet (CXHL2000200, CXHL2000201, ...)
May 28, 2020

New Preclinical Models for NASH Provide Strong Clinical Relevance and Shortened Timelines

Availability of two new preclinical models for Non-alcoholic steatohepatitis (NASH) that highly resemble clinical progression of the disease and do so ...
May 26, 2020

BioDuro & Silexon Form Strategic Collaboration to Develop New Anti-Cancer Drugs

BioDuro and Silexon collaborate on new anti-cancer drugs, leveraging advanced NASH models for accelerated preclinical testing and development | BioDuro-Sundia
May 26, 2020

BioDuro & neoX Partner to Create Next Generation Antibody Discovery Platform

BioDuro and neoX join forces to pioneer a synthetic antibody discovery platform, integrating AI and high-throughput screening to expedite development of
April 28, 2020

Sundia’s SARS-CoV-2 3CLpro assay is ready to meet the challenges of COVID-19 pandemic

Sundia's Biology team launches a SARS-CoV-2 3CLPro assay to aid in anti-COVID-19 drug development, utilizing high-throughput screening for effective protease i
April 18, 2020
Total 88 12...78910111213...1718
Subscribe to BioDuro-Sundia
Receive our newsletter and information on upcoming events
Your trusted partner from drug discovery and
development to commercialization

Home

About us

Services & Solutions

Platforms

News & Resources

Careers

Contact us

Explore

Discovery

Drug Substance

Drug Product

© 2023 BioDuro-Sundia. All rights reserved
Terms of Use Privacy Policy
We use necessary cookies to ensure our website functions properly and to keep it secure. These necessary cookies must be enabled. By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. You can personalize or withdraw your consent at any moment by clicking on the link "Cookies Settings". For more information on how we use cookies, including the total lifespan of cookies and the identity of third parties intervening on our website, please consult the Privacy Notice available in the site footer.
Accept all